This week

the insulin act passed committee and heads to the senate floor — and nobody in the debate is reading the mechanism

On August 8, 2026, [Forbes reported that the INSULIN Act of 2026 is advancing toward the Senate floor](https://www.forbes.com/sites/joshuacohen/2026/08/08/insulin-costs-drug-patent-reform-congress/), after passing the Senate Health, Education, Labor and Pensions Committee by a 17-to-5 vote in July. The bipartisan bill — introduced by Senators Raphael Warnock, Jeanne Shaheen, John Kennedy, and Susan Collins — would cap monthly out-of-pocket insulin costs at $35 for people with private insurance and restrict citizen-petition abuses that delay biosimilar market entry. [PBS NewsHour covered the ongoing effort](https://www.pbs.org/newshour/health/diabetes-advocates-hold-out-hope-as-a-bipartisan-bill-revives-efforts-to-lower-insulin-costs) as a rare bipartisan moment with patient advocates cautiously optimistic about its prospects. The debate is legitimate: approximately 37 million Americans have diabetes, and those who depend on insulin for survival have historically paid dramatically more for it in the United States than in comparable countries. What the coverage rarely pauses for is the molecule at the center of that debate. Insulin is not a drug class or an insurance line item — it is a 51-amino-acid peptide hormone, assembled and stored in beta cells, and released in response to glucose in the same way BPC-157 is a peptide, or semaglutide is a peptide, except that insulin has been keeping people alive for over 100 years and keeps getting more interesting every decade.

The actual molecule

insulin is a 51-amino-acid two-chain peptide that the pancreas assembles and fires in glucose-triggered pulses

Insulin is produced by beta cells in the islets of Langerhans — clusters of endocrine cells scattered through the pancreas — and it starts life as a single protein called preproinsulin before being cleaved twice to its final two-chain structure. The A-chain is 21 amino acids; the B-chain is 30; two disulfide bonds lock them together. In healthy beta cells, insulin is stored in hexameric form with zinc ions until rising blood glucose levels trigger release, at which point it fires in pulsatile bursts roughly every five to ten minutes. When insulin binds the insulin receptor — a receptor tyrosine kinase embedded in the cell membrane of muscle, adipose, and liver cells — it initiates a cascade that moves GLUT4 glucose transporters from intracellular storage to the cell surface, opening channels for glucose uptake. In the liver simultaneously, it promotes glycogen synthesis and suppresses glucagon-stimulated glucose output. Modern pharmaceutical insulins are engineered analogs: amino acid substitutions that alter absorption speed, peak time, and duration. [Insulin icodec, branded as Awiqli, was FDA-approved in March 2026](https://www.hcplive.com/view/fda-approves-awiqli-insulin-icodec-first-once-weekly-basal-insulin-for-type-2-diabetes) as the first once-weekly basal insulin, achieving mean HbA1c reductions of 1.55% versus 1.35% for daily glargine across the ONWARDS phase 3 program — the most significant pharmacokinetic update to basal insulin in years.

The public story

most of the political debate calls insulin a blood sugar drug and stops there — the biology does not stop there

The political conversation treats insulin as a commodity — something that should be inexpensive because it has been around since 1922 and the original patent was sold for $1. The public health conversation treats it as a necessity that has been repriced through product variation and formulary strategy. Both framings are correct. Neither explains why the molecule keeps getting more scientifically interesting. Insulin resistance — the underlying phenomenon in type 2 diabetes that drives up insulin requirements — is not simply a beta cell productivity problem. It reflects failures in insulin receptor signaling, GLUT4 trafficking, and post-receptor intracellular cascades in ways that modern pharmacology is still mapping. The GLP-1 drug era has added another dimension: people on semaglutide or tirzepatide routinely need less exogenous insulin than before, because GLP-1 receptor activation amplifies glucose-dependent insulin secretion from functioning beta cells and reduces glucagon output that would otherwise drive glucose higher. Insulin demand is shifting as the therapeutic landscape around it changes. This dynamic is not what Senate floor debates cover — but it is why the molecule at the center of the pricing fight is a more active scientific object than a century-old drug has any business being.

What the data says

insulin has more human evidence than any peptide in medicine — and in 2026 it got its first once-weekly engineering update

Insulin carries the Approved evidence tier because no other tier applies to a therapeutic peptide with more than a century of continuous clinical use and randomized controlled trials across every decade since at least the 1970s. [PubMed literature on insulin](https://pubmed.ncbi.nlm.nih.gov/?term=insulin+peptide+hormone) spans mechanism, clinical pharmacology, and comparative effectiveness across dozens of approved formulations. The Awiqli approval rested on the ONWARDS phase 3A program — five randomized active-controlled trials in approximately 4,000 adults with type 2 diabetes. ONWARDS 1 showed a mean HbA1c reduction of 1.55% with icodec versus 1.35% with glargine U100; ONWARDS 3 showed 1.57% versus 1.36% for degludec. [HCPLive reported on the FDA approval](https://www.hcplive.com/view/fda-approves-awiqli-insulin-icodec-first-once-weekly-basal-insulin-for-type-2-diabetes) as the first significant pharmacokinetic advancement in basal insulin in years — not a mechanism change, but a formulation change with real adherence implications for a population where daily injection is a genuine barrier to consistent use. For type 1 diabetes, the evidence context is categorically different: insulin is not one treatment option among alternatives. It is the only option. Its removal produces diabetic ketoacidosis, then coma, then death — a clinical fact that predates the randomized controlled trial methodology used to study every other peptide on this site.

Approved — PeptideFactCheck stance

the mechanism is settled, the market access fight is real, and the once-weekly era is just beginning

Insulin carries the Approved evidence tier, which here functions more as a floor than a ceiling — every other tier on this site would represent a downgrade the evidence cannot support. The INSULIN Act debate, tracked this week via [Forbes coverage of the Senate committee progress](https://www.forbes.com/sites/joshuacohen/2026/08/08/insulin-costs-drug-patent-reform-congress/) and [PBS NewsHour patient advocacy reporting](https://www.pbs.org/newshour/health/diabetes-advocates-hold-out-hope-as-a-bipartisan-bill-revives-efforts-to-lower-insulin-costs), is a market structure and patent argument — not a pharmacology argument. The molecule itself is not in dispute. What the next decade of insulin science will work through includes: how GLP-1 and dual-agonist drugs change the point at which insulin becomes necessary in a type 2 regimen, whether once-weekly formulations like Awiqli shift adherence enough to change real-world outcomes data, and how insulin resistance as a systems-level signaling failure responds to combination approaches that did not exist a generation ago. The pricing fight is legitimate. The biology is more interesting than the pricing fight. Both are happening simultaneously, right now in 2026, around the same 51-amino-acid peptide hormone that has been in clinical use longer than any drug most people will ever touch.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.